Glioblastoma Multiforme Treatment Market Size

Glioblastoma Multiforme Treatment Market size was valued at USD 2.9 billion in 2023 growing at a CAGR of 8.6% from 2024 and 2032, driven by factors such as the rising prevalence of glioblastoma.

For instance, as per the report published by American Brain Tumor Association, it has been estimated that glioblastomas represent about 14% of all primary brain tumours. On average, more than 12,000 glioblastoma cases are diagnosed each year in the U.S. Thus, the rapid increase in the prevalence of glioblastoma globally is the major factor that is anticipated to increase the demand for novel drug therapeutics and treatment procedures, thereby boosting the market growth.

Moreover, increase in investments in R&D by pharmaceutical companies and research institutions are leading to the discovery of new treatment modalities. Clinical trials and studies exploring immunotherapy, gene therapy, and personalized medicine are expanding the treatment landscape for glioblastoma multiforme that is anticipated to foster the growth of the market.

Glioblastoma (GBM), also referred to as a grade IV astrocytoma, is a fast-growing and aggressive brain tumor. It is the most malignant and pervasive subtype of glioma and is the most common primary brain tumor in adults. GBM has been classified into isocitrate dehydrogenase (IDH) wild-type and mutant variants. IDH variants bear the cytosine-phosphate-guanine (CpG) island methylation phenotype (G-CIMP).